Go-ahead for trials of electric drug delivery:
This article was originally published in Clinica
Trials of a device which uses electric fields to open pores in cells to deliver cancer drugs are to begin in Canada. The Phase II study will assess Genetronics Biomedical's MedPulser device as a way of delivering the drug Bleomycin in the treatment of advance head and neck tumours. Some 25 patients will be studied at four sites throughout Canada. Phase II trials have already begun in the US and the company said the preliminary data show that very low doses of the drug are effective.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.